NEW YORK – Hutchmed on Wednesday said it started a Phase I/IIa trial of its antibody-targeted therapy conjugate (ATTC) HMPL-A580 in patients with unresectable, advanced or metastatic solid tumors.
HUTCHMED has initiated a global phase 1/2a clinical trial of HMPL‑A580, its second antibody‑targeted therapy conjugate, in patients with unresectable, advanced or metastatic solid tumours in China and ...
HMPL-A580 is Hutchmed's second novel antibody-targeted therapy conjugate. It is under investigation for patients with unresectable, advanced or metastatic solid tumours in China and the US, with the ...
Second clinical candidate from HUTCHMED’s next-generation ATTC platform — — Leveraging synergy through simultaneous inhibition of PAM pathway and EGFR signaling — HONG KONG and SHANGHAI and FLORHAM ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results